Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for the phase I/II study of the experimental antiPD-1 anitbody MEDI0680 plus durvalumab (Imfinzi) versus nivolumab (Opdivo) monotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC) (NCT02118337).
The study was a randomized, open-label study evaluating the safety, efficacy, and the anti-tumor activity of the MEDI0680/durvalumab combination. The research hypothesis behind the evaluation was that monotherapy alone would not have an effect on all of the interactions between the cells and continue to inhibit the tumor microenvironment. Combinations of PD-1 and PD-L1 agents, on the other hand, can block the interactions between cells.